These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 6805621)

  • 61. Effect of dose on acetylator phenotype distribution of hydralazine.
    Timbrell JA; Harland SJ; Facchini V
    Clin Pharmacol Ther; 1981 Mar; 29(3):337-43. PubMed ID: 7471604
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Plasma concentration and acetylator phenotype determine response to oral hydralazine.
    Shepherd AM; McNay JL; Ludden TM; Lin MS; Musgrave GE
    Hypertension; 1981; 3(5):580-5. PubMed ID: 7298112
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Hydrallazine and beta-blockade in refractory hypertension with characterization of acetylator phenotype.
    Hunyor SN
    Aust N Z J Med; 1975 Dec; 5(6):530-6. PubMed ID: 7224
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Effect of oral dose size on hydralazine kinetics and vasodepressor response.
    Shepherd AM; Irvine NA; Ludden TM; Lin MS; McNay JL
    Clin Pharmacol Ther; 1984 Nov; 36(5):595-600. PubMed ID: 6488679
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Control of hypertension with single daily doses of sotalol hydrochloride.
    Gabriel R
    Curr Med Res Opin; 1976-1977; 4(10):739-42. PubMed ID: 1052165
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Effect of intravenous dose on hydralazine kinetics after administration.
    Ludden TM; Shepherd AM; McNay JL; Lin MS
    Clin Pharmacol Ther; 1983 Aug; 34(2):148-52. PubMed ID: 6872407
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Indomethacin does not attenuate the effects of hydralazine in normal subjects.
    Jackson SH; Pickles H
    Eur J Clin Pharmacol; 1983; 25(3):303-5. PubMed ID: 6414822
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Comparative bioavailability of a sustained-release ion-exchange hydralazine product with a potassium (cation) challenge.
    Woodworth JR; Ludden TM; Ludden LK; Shepherd AM; Rotenberg KS
    J Pharm Sci; 1992 Jun; 81(6):541-2. PubMed ID: 1522491
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Variability of plasma hydralazine concentrations in male hypertensive patients.
    Ludden TM; McNay JL; Shepherd AM; Lin MS
    Arthritis Rheum; 1981 Aug; 24(8):987-93. PubMed ID: 7284051
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Survival in hydralazine-treated hypertensive patients with and without late toxicity.
    Perry HM; Camel GH; Carmody SE; Ahmed KS; Perry EF
    J Chronic Dis; 1977 Aug; 30(8):519-28. PubMed ID: 893655
    [No Abstract]   [Full Text] [Related]  

  • 71. The hypotensive response to hydralazine, in triple therapy, is not related to acetylator phenotype.
    Vandenburg MJ; Wright P; Holmes J; Rogers HJ; Ahmad RA
    Br J Clin Pharmacol; 1982 May; 13(5):747-50. PubMed ID: 7082547
    [No Abstract]   [Full Text] [Related]  

  • 72. Bioavailability of standard and sugar-coated hydrallazine formulations in fast and slow acetylators [proceedings].
    Hawksworth GM; Morrice M; Petrie JC; Scott AK
    Br J Clin Pharmacol; 1980 Jan; 9(1):111P-112P. PubMed ID: 7356875
    [No Abstract]   [Full Text] [Related]  

  • 73. Hydralazine boluses for the treatment of severe hypertension in pre-eclampsia.
    Duley L
    Br J Obstet Gynaecol; 1995 Jul; 102(7):585. PubMed ID: 7647069
    [No Abstract]   [Full Text] [Related]  

  • 74. Hydralazine boluses for the treatment of severe hypertension in pre-eclampsia.
    Duley L
    Br J Obstet Gynaecol; 1995 Jan; 102(1):83. PubMed ID: 7833330
    [No Abstract]   [Full Text] [Related]  

  • 75. Three times daily or 8-hourly.
    Nigam R; Loveday BJ; Grainger SL; Maxton DG
    J R Soc Med; 1986 Jan; 79(1):15-6. PubMed ID: 3944813
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Comparison of once daily atenolol with slow release oxprenolol in hypertension.
    Cunnington AR; Waite MA
    Proc R Soc Med; 1977; 70(Suppl 5):21-3. PubMed ID: 20919339
    [No Abstract]   [Full Text] [Related]  

  • 77. The concept of strengthening blood pressure control dominates once again.
    Guo Y; Li G
    Hypertens Res; 2022 Feb; 45(2):382-383. PubMed ID: 34907339
    [No Abstract]   [Full Text] [Related]  

  • 78. Hydralazine in arterial hypertension. Randomized double-blind comparison of conventional/Slow-Release formulation and of b.i.d./q.i.d. dosage regimens.
    Wulff K; Lenz K; Krogsgaard AR; Holst B
    Acta Med Scand; 1980; 208(1-2):49-54. PubMed ID: 7435247
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Network-based approach highlighting interplay among anti-hypertensives: target coding-genes: diseases.
    Sharma R
    Sci Rep; 2020 Nov; 10(1):20152. PubMed ID: 33214616
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Evidence based general practice: a retrospective study of interventions in one training practice.
    Gill P; Dowell AC; Neal RD; Smith N; Heywood P; Wilson AE
    BMJ; 1996 Mar; 312(7034):819-21. PubMed ID: 8608291
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.